Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Rocuronium + remifentanil is a combination of two intravenous drugs commonly used in anesthesia. Rocuronium is a non-depolarizing neuromuscular blocking agent (muscle relaxant) that acts as a competitive antagonist at nicotinic acetylcholine receptors at the neuromuscular junction, leading to skeletal muscle relaxation and facilitating tracheal intubation or surgery. Remifentanil is an ultra-short-acting synthetic opioid analgesic that acts as an agonist at µ-opioid receptors, providing potent pain relief and blunting hemodynamic responses during surgical procedures. Remifentanil has rapid onset and offset due to its unique metabolism by nonspecific esterases in blood and tissues, independent of liver function[1][3][4][6]. The combination is used for induction and maintenance of general anesthesia, with remifentanil often administered before rocuronium to reduce withdrawal movements caused by rocuronium injection[2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on rocuronium + remifentanil.